The role of renin-angiotensin system in prothrombotic state in essential hypertension

Physiological Research

Volumn 59, Issue 1, 2010, Pages 13-23

  Remkova A ^a   Remko, M ^b  

^a Military Hospital   (Slovakia)

^b Physics and Informatics   (Slovakia)

Author keywords

Coagulation; Endothelium; Fibrinolysis; Hypertension; Platelet

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT;

ANIMAL; BLOOD; BLOOD CLOTTING; BLOOD PRESSURE; DRUG EFFECT; ENDOTHELIUM CELL; HUMAN; HYPERTENSION; METABOLISM; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; THROMBOCYTE; THROMBOSIS;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD COAGULATION; BLOOD PLATELETS; BLOOD PRESSURE; ENDOTHELIAL CELLS; FIBRINOLYTIC AGENTS; HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM; THROMBOSIS;

EID: 77952306480     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. ALEIL B, MEYER N, WOLFF V, KIENTZ D, WIESEL ML, GACHET C, CAZENAVE JP, LANZA F: Plasma glycoprotein V levels in the general population: normal distribution, associated parameters and implications for clinical studies. Thromb Haemost 96: 505-511, 2006.
2. ASO Y, WAKABAYASHI S, YAMAMOTO R, MATSUTOMO R, TAKEBAYASHI K, INUKAI T: Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes. Diabetes Care 28: 2211-2216, 2005.
3. ATALAR E, HAZNEDAROGLU IC, KILIC H, OZER N, COSKUN S, OZTURK E, AKSOYEK S, OVUNC K, KIRAZLI S, OZMEN F: Increased soluble glycoprotein V concentration during the acute onset of unstable angina pectoris in association with chronic cigarette smoking. Platelets 16: 329-333, 2005.
4. BAUERSACHS J, HECK M, FRACCAROLLO D, HILDEMANN SK, ERTL G, WEHLING M, CHRIST M: Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase suppression. J Am Coll Cardiol 39: 351-358, 2002.
5. BLANN AD, NAQVI T, WAITE M, MCCOLLUM CN: Von Willebrand factor and endothelial damage in essential hypertension. J Hum Hypertens 7: 107-111, 1993.
6. BLANN AD, LANZA F, GALAJDA P, GURNEY D, MOOG S, CAZENAVE JP, LIP GY: Increased platelet glycoprotein V levels in patients with coronary and peripheral atherosclerosis - the influence of aspirin and cigarette smoking. Thromb Haemost 86: 777-783, 2001.
7. BLANN AD, NADAR SK, LIP GYH: The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 24: 2166-2179, 2003.
8. CECONI C, FOX KM, REMME WJ, SIMOONS ML, BERTRAND M, PARRINELLO G, KLUFT C, BLANN A, COKKINOS D, FERRARI R on behalf of the EUROPA and the PERTINENT Investigators: ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 73: 237-246, 2007.
9. DIELIS AWJH, SMID M, SPRONK HMH, HOUBEN AJHM, HAMULYÁK K, KROON AA, TEN CATE H, DE LEEUW PW: Changes in fibrinolytic activity after angiotensin II receptor blockade in therapy-resistant hypertensive patients. J Thromb Haemost 5: 1509-1515, 2007.
10. ERDEM Y, USALAN C, HAZNEDAROGLU IC, ALTUN B, ARICI M, YASAVUL U, TURGAN C, CAGLAR S: Effects of angiotensin-converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens 12: 1071-1076, 1999.
11. ERLINGER TP, CONLIN PR, MACKO RF, BOHANNON AD, MILLER III ER, MOORE TJ, SVETKEY LP, APPEL LJ: The impact of angiotensin II receptor blockade and the DASH diet on markers of endogenous fibrinolysis. J Hum Hypertens 16: 391-397, 2002.
12. FERRARI R, ARBUSTINI E, BLANN A, COKKINOS D, KLUFT C, DE MAAT MPM, TAVAZZI L: PERTINENT - PERindopril - Thrombosis, InflammatioN, Endothelial dysfunction and Neurohormonal activation Trial: A sub-study of the EUROPA study. Cardiovasc Drug Ther 17: 83-91, 2003.
13. FOGARI R, ZOPPI A, LAZZARI P, PRETI P, MUGELLINI A, CORRADI L, LUSARDI P: ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J Cardiovasc Pharmacol 32: 616-620, 1998.
14. FOGARI R, ZOPPI A, PRETI P, FOGARI E, MALAMANI G, MUGELLINI A: Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women. Am J Hypertens 14: 921-926, 2001a.
15. FOGARI R, ZOPPI A, MALAMANI G, MARASI G, PESCE RM, BANDERALI A, MUGELLINI A: Effects of four angiotensin II-receptor antagonists on fibrinolysis in postmenopausal women in hypertension. Curr Ther Res Clin Exp 62: 68-78, 2001b.
16. FOGARI R, MUGELLINI A, ZOPPI, CORRADI L, PRETI P, LAZZARI P, DEROSA G: Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens 15 (part 1): 316-320, 2002.
17. GHIADONI L, MAGAGNA A, VERSARI D, KARDASZ I, HUANG Y, TADDEI S, SALVETTI A: Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 41: 1281-1286, 2003.
18. HLUBOCKÁ Z, UMNEROVÁ V, HELLER S, PELEŠKA J, JINDRA A, JÁCHYMOVÁ M, KVASNIČKA J, HORKÝ K, ASCHERMANN M: Circulating intercellular cell adhesion molecule-1, endothelin-1 and von Willebrand factor-markers on endothelial dysfunction in uncomplicated essential hypertension: the effect of treatment with ACE inhibitors. J Hum Hypertens 16: 557-562, 2002.
19. KISHI Y, OHTA S, KASUYA N, SAKITA S, ASHIKAGA T, ISOBE M: Perindopril augments ecto-ATP diphosphohydrolase activity and enhances endothelial anti-platelet function in human umbilical vein endothelial cells. J Hypertens 21: 1347-1353, 2003.
20. KOH KK, CHUNG WJ, AHN JY, HAN SH, KANG WC, SEO YH, AHN TH, CHOI IS, SHIN EK: Angiotensin II type receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo controlled study. Atherosclerosis 177: 155-160, 2004.
21. LEE KW, BLANN AD, LIP GY: High pulse pressure and nondipping circadian blood pressure in patients with coronary artery disease: relationship to thrombogenesis and endothelial damage/dysfunction. Am J Hypertens 18: 104-115, 2005.
22. LIP GYH, BLANN AD, EDMUNDS E, BEEVERS DG: Baseline abnormalities of endothelial function and thrombogenesis in relation to prognosis in essential hypertension. Blood Coagul Fibrinolys 13: 35-41, 2002.
23. LI-SAW-HEE FL, BEEVERS DG, LIP GYH: Effect of antihypertensive therapy using enalapril or losartan on haemostatic markers in essential hypertension: a pilot prospective randomised double-blind parallel group trial. Int J Cardiol 78: 241-246, 2001.
24. MA J, ALBORNOZ F, YU C, BYRNE DW, VAUGHAN DE, BROWN NJ: Differing effects of mineralocorticoid receptor-dependent and -independent potassium-sparing diuretics on fibrinolytic balance. Hypertension 46: 310-320, 2005.
25. MAKRIS TK, STAVROULAKIS GA, KRESPI PG, HATZIZACHARIAS AN, TRIPOSKIADIS FK, TSOUKALA CG, VOTTEAS VV, KYRIAKIDIS MK: Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. Am J Hypertens 13: 783-788, 2000.
26. MATSUMOTO T, MINAI K, HORIE H, OHIRA N, TAKASHIMA H, TARUTANI Y, YASUDA Y, OZAWA T, MATSUO S, KINOSHITA M, HORIE M: Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients. J Am Coll Cardiol 41: 1373-1379, 2003.
27. MONTÓN M, JIMÉNEZ A, NÚNEZ A, LÓPEZ-BLAYA A, FARRÉ J, GÓMEZ J, ZALBA LR, SÁNCHEZ DE MIGUEL L, CASADO S, LÓPEZ-FARRÉ A: Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation. J Cardiovasc Pharmacol 35: 906-913, 2000.
28. NADAR SK, BLANN AD, KAMATH S, BEEVERS DG, LIP GY: Platelet indexes in relation to target organ damage in high-risk hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Am Coll Cardiol 44: 415-422, 2004a.
29. NADAR SK, BLANN AD, LIP GY: Platelet morphology and plasma indices of platelet activation in essential hypertension: effects of amlodipine-based antihypertensive therapy. Ann Med 36: 552-557, 2004b.
30. NADAR SK, BLANN AD, LIP GY: Platelet morphology, soluble P selectin and platelet P-selectin in acute ischaemic stroke. The West Birmingham Stroke Project. Thromb Haemost 92: 1342-1348, 2004c.
31. NAGEL JM, TIETZ AB, GO{double acute}KE B, PARHOFER KG: The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metabolism 55: 1149-1154, 2006.
32. OKRUCKÁ-REMKOVÁ A, PECHÁN J, KRATOCHVÍĽOVÁ H: Effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril on endothelial and platelet functions in essential hypertension. Platelets 9: 63-67, 1998.
33. POLI KA, TOFLER GH, LARSON MG, EVANS JC, SUTHERLAND PA, LIPINSKA I, MITTLEMAN MA, MULLER JE, D'AGOSTINO RB, WILSON PWF, LEVY D: Association of blood pressure with fibrinolytic potential in the Framingham Offspring Study. Circulation 101: 264-269, 2000.
34. RIONDINO S, PIGNATELLI P, PULCINELLI FM, LENTI L, DI VEROLI C, MARIGLIANO V, GAZZANIGA PP: Platelet hyperactivity in hypertensive older patients is controlled by lowering blood pressure. J Am Geriatr Soc 47: 943-947, 1999.
35. REMKOVÁ A, KRATOCHVÍĽOVÁ H: Effect of the angiotensin-converting enzyme inhibitor perindopril on haemostasis in essential hypertension. Blood Coagul Fibrinolys 7: 641-644, 2000.
36. REMKOVÁ A, KRATOCHVÍĽOVÁ H: Effect of the new centrally acting antihypertensive agent rilmenidine on endothelial and platelet function in essential hypertension. J Hum Hypertens 16: 549-555, 2002.
37. REMKOVÁ A, KOVÁČOVÁ E, PRIKAZSKÁ M, KRATOCHVÍĽOVÁ H: Thrombomodulin as a marker of endothelium damage in some clinical conditions. Eur J Intern Med 11: 79-84, 2000.
38. REMKOVÁ A, KRATOCHVÍĽOVÁ H, ĎURINA J: Impact of the therapy by renin-angiotensin system targeting antihypertensive agents perindopril versus telmisartan on prothrombotic state in essential hypertension. J Hum Hypertens 22: 338-345, 2008.
39. RUIZ-ORTEGA M, ESTEBAN V, EGIDO J: The regulation of the inflammatory response through nuclear factor-(B pathway by angiotensin IV extends the role of the renin angiotensin system in cardiovascular diseases. Trends Cardiovasc Med 17: 19-25, 2007.
40. SAKATA K, PAWLAK R, URANO T, TAKADA A: Effects of a long-term pharmacological interruption of the renin-angiotensin system on the fibrinolytic system in essential hypertension. Pathophysiol Haemost Thromb 32: 67-75, 2002.
41. SAPOSNIK B, RENY JL, GAUSSEM P, EMMERICH J, AIACH M, GANDRILLE S: A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is candidate risk factor for thrombosis. Blood 103: 1311-1318, 2004.
42. SAWATHIPARNICH P, MURPHEY LJ, KUMAR S, VAUGHAN DE, BROWN NJ: Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1. J Clin Endocrinol Metab 88: 3867-3873, 2003.
43. SECHI LA, ZINGARO L, CATENA C, CASACCIO D, DE MARCHI S: Relationship of fibrinogen levels and hemostatic abnormalities with organ damage in hypertension. Hypertension 36: 978-985, 2000.
44. SECHI LA, NOVELLO M, COLUSSI G, DI FABIO A, CHIUCH A, NADALINI E, CASANOVA-BORCA A, UZZAU A, CATENA C: Relationship of plasma renin with a prothrombotic state in hypertension: relevance for organ damage. Am J Hypertens 21: 1347-1353, 2008.
45. SEREBRUANY VL, MALININ A, BARSNESS G, VAHABI J, ATAR D: Effects of aliskiren, a renin inhibitor, on biomarkers of platelet activity, coagulation and fibrinolysis in subjects with multiple risk factors for vascular disease. J Hum Hypertens 22: 303-310, 2008.
46. SHAO J, NANGAKU M, INAGI R, KATO H, MIYATA T, MATSUSAKA T, NOIRI E, FUJITA T: Receptor-independent intracellular radical scavenging activity of an angiotensin II receptor blocker. J Hypertens 25: 1643-1649, 2007.
47. SCHÄFER A, FRACCAROLLO D, HILDEMANN S, CHRIST M, EIGENTHALER M, KOBSAR A, WALTER U, BAUERSACHS J: Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition. Thromb Haemost 89: 1024-1030, 2003.
48. SPENCER CGC, MARTIN SC, FELMDEN DC, BLANN AD, BEEVERS GD, LIP GYH: Relationship of homocysteine to markers of platelet and endothelial activation in 'high ris' hypertensives: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. Int J Cardiol 94: 293-300, 2004.
49. STRAGIER B, DE BUNDEL D, SARRE S, SMOLDERS I, VAUQELIN G, DUPONT A, MICHOTTE Y, VANDERHEYDEN P: Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review. Heart Fail Rev 13: 321-327, 2008.
50. TADDEI S, VIRDIS A, GHIADONI L, SUDANO I, SALVETTI A: Effects of antihypertensive drugs on endothelial dysfunction - clinical implications. Drugs 62: 265-284, 2002.
51. TAY KH, LIP GYH: What "drives" the link between the renin-angiotensin-aldosterone system and the prothrombotic state in hypertension? Am J Hypertens 22: 1278-1279, 2008.
52. THE EUROPEAN TRIAL ON REDUCTION OF CARDIAC EVENTS WITH PERINDOPRIL IN STABLE ARTERY DISEASE INVESTIGATORS: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (EUROPA). Lancet 362: 782-788, 2003.
53. TOMIYAMA H, KIMURA Y, MITSUHASHI H, KINOUCHI T, YOSHIDA H, KUSHIRO T, DOBA N: Relationship between endothelial function and fibrinolysis in early hypertension. Hypertension 31: 321-327, 1998.
54. TRIFILETTI A, BARBERA N, SCAMARDI R, BAGNATO L, PIZZOLEO MA, NEVOSO A, LASCO A, PEDULLA M, FRISINA N: Effects of medium-term antihypertensive therapy on haemostatic parameters in patients with essential hypertension. Haemostasis 27: 35-38, 1997.
55. VISCHER UM: Von Willebrand factor, endothelial dysfunction and cardiovascular disease. J Thromb Haemost 4: 1186-1193, 2006.
56. WOLFF V, ALEIL B, GIROUD M, LORENZINI JL, MEYER N, WIESEL ML, CAZENAVE JP, LANZA F: Soluble platelet glycoprotein V is a marker of thrombosis in patients with ischemic stroke. Stroke 36: e17-e19, 2005.